• Fresh issue size: It provides a fresh issue size of 44,52,064 Equity shares of a face value of 10.

• Offer for sale: It provides an offer for sale of up to 22,99,936 equity shares of face value of 10.
• Price Range: The price band is fixed between Rs. 151- 159 per equity share.
• Issue Type: The IPO is a 100% book-built offer.
• Subscription date: The issue period begins on February 10th 2025 and ends on February 12th  2025.
• Lot size: It is providing a lot size of 800.
• Listing Date: The IPO is going to be listed on February 17th , 2025.
• Stock Exchange: The IPO is going to be listed on the Emerge platform of  NSE Limited.

The company with the help of this IPO aims to expand its operation by setting up new flagship centers in Jankipuram, Ayodhya and Ashiyana Uttar Pradesh and further utilize the net proceeds for general corporate purposes.

The table below (in lakhs) stipulates the restated Financial Information of the company for the last three financial years for the period ended on December 31, 2024, 

India is witnessing a drastic increase in the health sector with the hospital market constitutes and contributing 80%. The country was also ranked 10th in the Medical Tourism Index in 2021-22 and foreign medical tourism increased from 1.83 lakh in 2020 to 5.04 lakh in 2023.

The Indian healthcare industry is driven by both the private and government sectors and is currently valued at 372 billion.

With the rapid increase of healthcare infrastructure, rising pharmacy care, health-tech, consumers and medical tourism in India along with the constant support from the government to strengthen healthcare and foreign parties investing in India, the healthcare market has improved significantly from 2016 to 2022 at CAGR of 22.52% and is projected to grow at a CAGR of 18.24% and reach 18,348.78 Billion rupees by FY 2027.  

• The company provides comprehensive services and a one-stop solution for all kinds of pathology and radiology services and is operative in Uttar Pradesh Uttarkhand and Rajasthan with 9 central laboratories, 27 satellite laboratories and more than 300 collection centers where few of the centers are NABL and NABH accredited.

• The company as of December 2024 carried out 55.79 lakh tests on about 17.11 lakh patients.
• The company’s subsidiary i.e. Chandan Hospital Ltd is operative with 31 shops in UP and Uttarkhand with the sale of all kinds of pharmaceutical products.
• The company has a strong business presence and dedicated team and aims to enhance its services by boosting its strategic B2B  and corporate partnerships.

• The company primarily operates in 23 cities in the state of Uttar Pradesh and 19 cities in the state of Uttarkhand, where its major revenue is generated, any political, economic or geographical disruption may adversely affect the business operations and financial conditions of the company.

• The company has 39 flagship centers across Uttar Pradesh, Uttarkhand and Rajasthan, any unforeseeable events, regulatory issues, facility malfunctions, customer services and satisfaction etc in these centers may lead to loss of operation ultimately impacting the business condition.
• The company is majorly reliant on its group company i.e. Chandan Hospital Ltd for its revenue generation, any changes in the terms and conditions with the group company may adversely affect the business operations and financial conditions of the company.
• The company largely depends on third-party suppliers particularly the state of UP for the supply of medical consumables, any disruption in the chain of supplies, the political scenario in the concerned supplier state, or failure to maintain alternative arrangements, may adversely affect the company operations and financial conditions.
• The company, its promoters and its directors are facing certain pending litigation any outcome of this proceeding may impact the company's operations and financial conditions.

The healthcare industry in India is significantly growing given the massive consumer demand along with private and government investments. It has always been a constant endeavor of the country to promote and access better health care in India.

The healthcare market is projected to grow at a CAGR of 18.24% and reach  Rupees 18,348.78 Billion by FY 2027. The company has made a strong business presence in the states of UP and Uttarkhand and has witnessed significant financial growth increasing its revenue from operations from Rs.11,956.35 Lakhs in 2022 to Rs. 17,659.01 Lakhs in 2024 with Rs. 16,747.47 lakhs for the period ended December 31, 2024.

The company also faces strong competition from well-established companies in this sector.

Potential investors should access the risks given in the RHP draft before investing.

The company with the help of this IPO plans to expand its operation by setting up new flagship centers in UP and further implement the net proceeds for general corporate purposes.

The company has shown stable returns and strong fundamentals.

Prospective investors should go through the details given in the RHP draft prospectus before investing.